Utility of Presepsin in Distinguishing Between Sepsis and SIRS

NCT02052895 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 226

Last updated 2018-08-21

Study results available
· View outcomes & findings →

Summary

This is an observational study to evaluate the diagnostic accuracy of presepsin levels to discriminate between sepsis and SIRS upon presentation with critical illness compatible with either sepsis or systemic inflammatory response syndrome (SIRS).

Conditions

Sponsors & Collaborators

  • Mochida Pharmaceutical Company, Ltd.

    lead INDUSTRY

Principal Investigators

  • Stanley Nasraway, MD, FCCM · Tufts Medical Center

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2015-07-31
Completion
2015-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02052895 on ClinicalTrials.gov